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Background: Pro-inflammatory cytokines are known to have deleterious effects on Schwann cells (SCs). Interleukin
17 (IL-17) is a potent pro-inflammatory cytokine that exhibits relevant effects during inflammation in the peripheral
nervous system (PNS), and IL-17-secreting cells have been reported within the endoneurium in proximity to the SCs.
Methods: Here, we analyzed the effects of IL-17 on myelination and the immunological properties of SCs. Dorsal root
ganglia (DRG) co-cultures containing neurons and SCs from BL6 mice were used to define the impact of IL-17 on
myelination and on SC differentiation; primary SCs were analyzed for RNA and protein expression to define the putative
immunological alignment of the SCs.
Results: SCs were found to functionally express the IL-17 receptors A and B. In DRG cultures, stimulation with IL-17
resulted in reduced myelin synthesis, while pro-myelin gene expression was suppressed at the mRNA level. Neuronal
outgrowth and SC viability, as well as structural myelin formation, remained unaffected. Co-cultures exhibited SC-
relevant pro-inflammatory markers, such as matrix metalloproteinase 9 and SCs significantly increased the expression of
the major histocompatibility complex (MHC) I and exhibited a slight, nonsignificant increase in expression of MHCII, and
a transporter associated with antigen presentation (TAP) II molecules relevant for antigen processing and presentation.
Conclusions: IL-17 may act as a myelin-suppressive mediator in the peripheral nerve, directly propagating SC-mediated
demyelination, paralleled by an inflammatory alignment of the SCs. Further analyses are warranted to elucidate the role
of IL-17 during inflammation in the PNS in vivo, which could be useful in the development of target therapies.
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Immune-mediated neuropathies represent a heteroge-
neous group of mainly demyelinating conditions, includ-
ing chronic inflammatory demyelinating polyneuropathy
(CIDP) and Guillain-Barré syndrome (GBS). Both condi-
tions are caused by an autoimmune response to peripheral
nerve antigens leading to inflammation, followed by glial
and neuronal damage. The underlying molecular mechan-
ism of these diseases still remains mainly unclear.
Interleukin (IL)-17 exhibits relevant effects during in-
flammation in the peripheral nervous system (PNS) [1]. In
addition, in chronic constriction injury of the sciatic nerve,
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unless otherwise stated.and contribute to myelin damage [2]; furthermore, IL-17
mediates a role in ensuing neuropathic pain [3].
IL-17 is a mainly pro-inflammatory cytokine, which is
expressed by CD4+ effector T helper cells (Th17 lineage),
as well as by other immune cells, such as neutrophils and
eosinophils [4-7].
Secretion of IL-17 by peripheral blood mononuclear
cells (PBMCs) in CIDP patients with disease activity was
found to be elevated compared with controls, and also
elevated in active CIDP patients compared with those in
remission; other interleukins did not show this correl-
ation [8]. Even in the absence of cerebrospinal fluid
(CSF) pleocytosis, IL-17 was found to be elevated in the
CSF of CIDP patients, showing a strong positive correlation
with CSF protein concentration [9]. Chi et al. detected an
increase in Th17+ cell populations in the CSF of active
CIDP patients [10]. These results suggest an involvementl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In an animal model of GBS, IL-17 was shown to be
present in rat sciatic nerves after induction of experi-
mental autoimmune neuritis [11]; IL-17 seemed to play
a role [12], particularly in the induction phase of the
condition. Additionally, CSF and plasma levels of IL-17
and IL-22 were found to be elevated in GBS patients
compared with healthy controls, and the IL-17 and the
related IL-22 levels in the CSF correlated with the GBS
disability scale scores [13]. All these studies claim a cru-
cial role for IL-17 but fail to decipher the molecular
mechanism of IL-17 in the inflamed peripheral nerve.
The fact that IL-17 is present in the inflamed periph-
eral nerve and that the corresponding receptor (IL-17
receptor (IL-17R)), is ubiquitously expressed [14] may
suggest a direct effect of IL-17 on Schwann cells (SCs).
SCs play the undisputable leading role in myelinating
peripheral nerves as well as in remyelination after injury
[15], thereby ensuring signal transmission and main-
tenance of neuronal homeostasis. Besides these properties,
SCs orchestrate PNS immunology, similar to non-
myelinating astrocytes in the central nervous system [16].
To this end, SCs possess the ability to secrete cytokines
and modify and express antigens on the major histocom-
patibility complex (MHC) on their surface [17,18]. As
immune-qualified glia, SCs functionally express high levels
of toll-like receptors (TLRs), mainly TLR3 and TLR4,
which respond to their respective ligands [19]. Various in-
flammatory or pro-inflammatory mediators are reported
to modulate SC homeostasis, such as interleukins, indu-
cible nitric oxide synthase (iNOS), cyclo-oxygenase-2
(COX-2), and matrix metalloproteinases (MMPs), some of
them in an autocrine or paracrine manner, as a particular
response to the surrounding environment [20-24]. As
such, the inflammatory mediator tumor necrosis factor α
(TNF-α) promotes phenotype reversion of mature SCs to
immature SCs [25-27].
These results are most likely just fragments towards
our understanding of the complex signaling of SC differ-
entiation to myelination or an immune-active pheno-
type. In order to define the impact of IL-17 on SC
differentiation and to detect a putative immunological
alignment of the SCs, we analyzed the effect of IL-17 on
myelinating dorsal root ganglia (DRG) co-cultures and
on purified SC cultures.
Methods
Primary Schwann cell cultures
Mouse SCs (mSCs) were prepared using a modified
Brockes method [28]. Cells were purified and cultured as
described before [29]. Briefly, sciatic nerves were dissected
from neonatal (postnatal day 3 (P3)) C57BL/6 mice and
digested with 0.05% collagenase (Worthington, Lakewood,NJ, USA) and 0.125% trypsin (Merck, Darmstadt, Germany).
Cells were plated in poly-D-lysine (PDL)-coated (Sigma-
Aldrich Corp., St. Louis, MO, USA) cell culture dishes
(Greiner Bio-One GmbH, Frickenhausen, Germany) with
Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen
Corp., Carlsbad, CA, USA) containing 10% horse serum
(HS; Invitrogen Corp., Carlsbad, CA, USA), 4 mM L-glu-
tamine ((Glut) Invitrogen Corp., Carlsbad, CA, USA),
2 ng/mL human heregulin β-1 (Cell Sciences, Canton,
MA, USA), 0.5 μM forskolin (FKL) (Sigma-Aldrich Corp.,
St. Louis, MO, USA) and 100 IU/mL penicillin/strepto-
mycin (PS; Invitrogen Corp., Carlsbad, CA, USA). For
complement lysis, cells were washed with Hank’s Balanced
Salt Solution (HBSS; Invitrogen Corp., Carlsbad, CA,
USA) containing 4-(2-hydroxyethyl)-1-piperazine ethane
sulfonic acid (HEPES; Invitrogen Corp., Carlsbad, CA,
USA) and subsequently incubated with DMEM, contain-
ing HEPES, HS, Glut, P/S and anti-thymidine 1.2 antibody
(AbD Serotec, Kidlington, UK). After 15 min at 37°C,
rabbit complement (Cedarlane Laboratories Inc., Burling-
ton, NC, USA) was added and incubated for 2 h at room
temperature (RT). Cells were washed twice using HBSS
containing HEPES and cultured on PDL-coated culture
dishes in DMEM medium, containing 10% HS (Invitrogen
Corp., Carlsbad, CA, USA), 4 mM Glut (Invitrogen Corp.,
Carlsbad, CA, USA), 2 ng/mL human heregulin β-1 (Cell
Sciences, Canton, MA, USA), 0.5 μM forskolin (Sigma-
Aldrich Corp., St. Louis, MO, USA), 20 μg/mL pituitary
extract bovine (PEB, Merck Millipore, Darmstadt,
Germany), 10 ng/mL recombinant human fibroblast
growth factor (Biomol GmbH, Hamburg, Germany),
100 IU/mL P/S (Invitrogen Corp., Carlsbad, CA, USA) and
1:4 mouse DRG supernatants; the medium was renewed
every third or second day.
Preparation of rat SCs (rSCs) was performed using the
modified Brockes method [28]. Sciatic nerves were dis-
sected from neonatal (P3) Wistar rats, digested with
0.1% collagenase (Worthington, Lakewood, NJ, USA)
and 0.25% trypsin (Invitrogen Corp., Carlsbad, CA,
USA), and cells were finally plated with DMEM contain-
ing 10% fetal calf serum (FCS). Cultures were treated
with two cycles of 10 μM cytosine arabinoside to reduce
fibroblasts, followed by complement lysis with anti-
thymidine 1.1 antibodies. Cultures reached a final purity
of more than 95% and were maintained in DMEM Gibco
3185 (Invitrogen Corp., Carlsbad, CA, USA) with 10%
FCS, 100 IU/mL P/S, 2 mM Glut, and 1 μL/mL FKL on
PDL-coated culture dishes.
Preparation of dorsal root ganglia
DRGs were prepared from embryonic day 15 (E15)
C57BL/6 mice (BL6) by opening the cutis and subcutis
along the spine and removing the spinal cord. DRG were
collected, centrifuged and resuspended [29,30]. Twenty-
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Germany) were pre-coated twice with collagen type I
(Becton Dickinson AG, Franklin Lakes, New Jersey,
USA) and 0.02 N acetic acid (1:6) (Carl Roth GmbH,
Karlsruhe, Germany), before plating the ganglia cells.
The DRG cultures were kept in neurobasal medium for
7 days, DMEM medium containing (BioWhittacker,
Lonza Group AG, Basel, Switzerland), 2 mM Glut (Invi-
trogen Corp., Carlsbad, CA, USA) 10% HS (Invitrogen
Corp., Carlsbad, CA, USA), 100 IU/L P/S (Invitrogen
Corp., Carlsbad, CA, USA), 100 ng/mL nerve growth
factor (NGF; Sigma-Aldrich corp., St. Louis, MO, USA),
and 4 g/L glucose (Sigma-Aldrich Corp., St. Louis, MO,
USA). After 1 week of culture, neurobasal medium
was exchanged for myelination media containing min-
imal essential media (MEM, Invitrogen Corp., Carlsbad,
CA, USA), 20 μg/mL PEB (Merck Millipore, Darmstadt,
Germany), 50 mg/L L-ascorbic acid (AA, Sigma-Aldrich
Corp., St. Louis, MO, USA), 0.5 μM FKL (Sigma-Aldrich
Corp., St. Louis, MO, USA), 2 mM L-glut (Invitrogen Corp.,
Carlsbad, CA, USA), 5% HS (Invitrogen Corp., Carlsbad,
CA, USA), 1× N2-supplement (N2; Invitrogen Corp.,
Carlsbad, CA, USA), 4 g/L D-(+)-glucose 10% (Sigma-
Aldrich Corp., St. Louis, MO, USA), and 50 ng/mL NGF
(Sigma-Aldrich Corp., St. Louis, MO, USA). The culture
myelination medium was renewed every 3 to 4 days. Cul-
tures were kept for 28 days in vitro and treated as indi-
cated from the sixth day after explantation until fixation,
followed by staining.
Immunocytochemistry
For immunocytochemistry, cells grown on glass cover slips
were initially washed with phosphate-buffered saline solu-
tion (PBS) and fixed with 4% paraformaldehyde (PFA;
Merck, Darmstadt, Germany) for 30 min for NF-L (neuro-
filament L) and 10 min for IL-17 receptor (IL-17R), follow-
ing another washing step with PBS containing 1% bovine
serum albumin (BSA; Sigma-Aldrich Corp., St. Louis, MO,
USA). Samples were blocked using PBS-based blocking so-
lution containing 10% (NF-L) or 4% (IL-17R) natural goat
serum (NGS, DAKO, Hamburg, Germany) and 0.1% (NF-
L) or 0.2% (IL-17R) Triton X-100 (Merck, Darmstadt,
Germany) for 30 min at RT. We used primary antibodies
against IL-17 receptor A (IL-17R A; Abcam, Cambridge,
UK), IL-17 receptor B (IL-17R B; Abcam, Cambridge, UK),
and rabbit anti-NF-L (Millipore, Billerica, MA, USA), each
diluted 1:400. Furthermore, antibodies against MHCI
(1:750, mouse monoclonal antibody; Novus Biologicals,
Littleton, CO, USA), MHCII (1:50, mouse monoclonal
antibody; AbD Serotec Kidlington, UK) and transporter as-
sociated with antigen presentation (TAP) II (1:200, rabbit
polyclonal; Bioss, Woburn, MA, USA) were used.
Primary antibodies were diluted in PBS, containing
0.1% Triton (0.05% for the MHCI antibody), 10% NGS,and for MHCII, an additional 0.25% BSA. Cells were in-
cubated for 1 hour at 37°C (overnight at 4°C for NF-L).
After three washing cycles with PBS, the secondary anti-
body was applied for 1 hour at RT. The following sec-
ondary antibodies were used: Alexa Fluor™ 594 goat
anti-rabbit, Alexa Fluor™ 594 mouse anti-rabbit, Alexa
Fluor™ 594 goat anti-rabbit (Invitrogen Corp., Carlsbad,
CA, USA), 1:200 diluted in PBS and 1% BSA (Sigma-
Aldrich Corp., St. Louis, MO, USA) and for NF-L 1:400
diluted in antibody diluent, followed by three washing
cycles with PBS. Samples were embedded in 4′,6-diami-
dine-2′-phenylindole dihydrochloride (DAPI) containing
mounting medium (Vectashield™, Vector Laboratories
Inc., Burlingame, CA, USA) and analyzed with an upright
fluorescence microscope (Nikon Eclipse TE200, Nikon
AG, Tokyo, Japan and Axioplan 2 Imaging, Zeiss, Oberko-
chen, Germany).
Real-time polymerase chain reaction
Total cellular RNA was extracted using an RNeasy™
Mini Kit (Qiagen, Hilden, Germany) and quantified by
NanoDrop-1000 (PEQLAB, Erlangen, Germany). Cells
were washed twice with PBS and detached with buffer
RLT. Total RNA (400 ng) was applied as matrix for
cDNA synthesis using TaqMan™ Reverse Transcription
Reagents (Applied Biosystems, Foster City, CA, USA)
and High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA) in accord-
ance with the manufacturer’s protocol (10 min at 25°C,
120 min at 37°C, and 5 min at 85°C). For subsequent
real-time polymerase chain reaction (rtPCR) the thermal
cycler (AbiPrism7000, Foster City, CA, USA) was set to
run for 2 min at 50°C, 10 min at 95°C, 40 cycles at 95°C
for 15 sec, and 1 min at 60°C. Power SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA)
and TaqMan™ Universal PCR Mastermix (Applied Bio-
systems, Foster City, CA, USA) were used. cDNA was
inserted for amplification at a final concentration of
0.6 μM for each primer. rtPCR was followed by a melt-
ing curve analysis. Overall, the experiments were per-
formed with the housekeeping genes 18S (rRNA probe
dye, VIC-MGB, Applied Biosystems, Foster City, CA,
USA) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) to calculate ΔΔct and shown as expression
correlated to housekeeping gene and control expression
[31]. cDNA was amplified with the following primers:
for IL-17A, 5′-TGG GAT CTG TCA TCG TGC T-3′
and 5′-ATC ACC ATG TTT CTC TTG ATC G-3′; for
IL-17B: 5′-GGA CAG CCC TTC TTT GTC TG-3′ and
5′-TGC TTT TTA TAT TTC ATT ACG TGG TT-3′;
for IL-17C, 5′-CCA CCC CAA CCT CTG TGT-3′ and
5′-CAA GGA GTC AGC CCA CGA-3′; for P0, 5′-ACC
TTC AAG GAG CGC ATC C-3′ and 5′- GCC ATC
CTT CCA GCT AGG GT -3′; for KROX-20, 5′-CTG
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GAG AAG GTG GGA CA-3′. Four independent experi-
ments were performed, and for each experiment, three
PCR runs, each in triplicate, were analyzed.
Sudan staining
Cultures were stained with Sudan black dye to assess
in vitro myelination [32]. Sudan staining has been ap-
proved before as an efficient and reliable method for
myelin quantification in DRG co-cultures [29]. After
washing twice with PBS, cells were fixed for 1 hour
using 4% PFA (Sigma-Aldrich Corp., St. Louis, MO,
USA), then washed twice again with PBS and treated
with 0.1% osmium tetroxide (Sigma-Aldrich corp., St.
Louis, MO, USA) for 1 hour. After sequential ethanol
treatment (25%, 50%, 70%, each for 5 min), myelin was
stained using 0.5% Sudan black (Flukan, Zurich,
Switzerland) dissolved in 70% ethanol for 1 hour,
followed by treatment with ethanol at decreasing con-
centrations (70%, 50%, 25% each for 1 min). Myelin was
analyzed after Sudan-Black staining, using an upright
microscope (Nikon Eclipse TE200, Nikon AG, Tokyo,
Japan). The complete cell layer was recorded using a 20x
objective, and individual pictures were reconstructed
using Adobe Photoshop (version 8.0, Adobe Systems In-
corporated, Delaware, USA). Quantification was per-
formed by counting the number of internodes and
correlating them to the number of neurons within the
cultures. Counting was performed using ImageJ (version
1.41o, National Institutes of Health, USA). To account
for inter-experimental variability of the quotient, data
are shown on an ordinal scale and normalized to 100%.
Electron microscopy
DRG co-cultures were grown on collagen-coated plastic
dishes, washed with PBS, and fixed for 12 h with 1% glu-
taraldehyde (Serva GmbH, Heidelberg, Germany) and
6% tannin (Merck KGaA, Darmstadt, Germany) in 0.1 M
cacodylate buffer (Merck KGaA, Darmstadt, Germany),
followed by postfixation in 1% osmium tetroxide (Sigma-
Aldrich Corp., St. Louis, MO, USA) for 1 h, dehydrated
using a series of alcohol, and finally embedded in Epon.
Ultrathin sections were prepared from regions of interest
and analyzed by electron microscopy (EM 910; Carl Zeiss,
Oberkochen, Germany).
Viability assay
A CellTiter-Blue™ Assay (Promega, Madison, WI, USA)
was performed to measure cell viability after IL-17
stimulation for 10 days in vitro. Analysis was performed
with cells grown in 96-well plates (Greiner Bio-One AG,
Frickenhausen, Germany), 12 samples per concentration
and three independent experiments were performed.
The CellTiter-Blue™ reagent was added directly to cellscultured in serum-supplemented medium. After an incu-
bation period of 1 to 3 h, spectral data (579Ex/584Em)
were recorded using a GENios-Pro reader (LI-COR Bio-
sciences, Bad Homburg, Germany) and analyzed
statistically.
MMP-9 and MMP-2 activity
Gelatinase activity was measured by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS/PAGE)
as described before [32,33]. A 12 μL amount of culture
supernatants was incubated with Novex™ Tris-glycine
sodium dodecyl sulfate sample buffer and applied to a
10% polyacrylamide gel (Bio-Rad Laboratories, Hercules,
CA, USA) containing 0.1% sodium dodecyl sulfate
(Sigma-Aldrich Corp., St. Louis, MO, USA) and 0.1%
gelatin from porcine skin (Sigma-Aldrich Corp., St.
Louis, MO, USA); the stacking gels were 5% polyacryl-
amide gels. After electrophoresis and washing, incuba-
tion in Novex™ Zymogram developing buffer (Invitrogen
Corp., Carlsbad, CA, USA) for 20 h at RT was followed
by staining for 3 h in 30% methanol (Merck, Darmstadt,
Germany), 10% acetic acid (Carl Roth GmbH, Karlsruhe,
Germany) containing 0.5% Coomassie brilliant blue
(Sigma-Aldrich Corp., St. Louis, MO, USA). Finally, gels
were destained using staining buffer without dye. Gelati-
nase activity was quantified using densitometry of un-
stained bands representing the areas of gelatin digestion.
Densitometry was performed using ImageJ, a public do-
main image processing program (version 1.41o, National
Institutes of Health, USA).
Statistical analysis
Four independent experiments were performed for
rtPCR, and for each experiment, three PCR runs, each
in triplicate, were analyzed. For the Sudan staining three
independent experiments were performed, each analyz-
ing 10 wells for each condition and for each 10.000 in-
ternodes were counted. Statistical myelin quantification
comprises three independent experiments, internodal
length is displayed as one representative experiment; an
analysis of variance between the three independent
experiments revealed no significant difference. For im-
munocytochemistry (IL-17R, MHCI, TAPII, MHCII) three
independent experiments were performed, each with 12
wells for each condition. The graphs depict one represen-
tative experiment with the analysis of 50 sectors of the cell
layer in each well. An analysis of variance between the
three independent experiments revealed no significant
difference.
Immunocytochemistry of neurofilament is graphed for
three independent experiments.
Electron Microscopy was performed in at least three in-
dependent experiments; graph for viability analysis shows
results of three independent experiments in a 96-well
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graphs show densitometry of one representative experi-
ment out of four; due to the difficulties in comparing dif-
ferent zymography-runs (for example, background), we
present the results of one experiment.
Statistical analysis (mean, standard deviation, and P
values) was performed with GraphPad Prism software
version 4.0 (GraphPad Software, Inc., La Jolla, CA,
USA). Calculations involved unpaired t-tests respectively
at 95% confidence interval, one-way ANOVA with
Bonferroni and Dunnett’s test (Figure 1G-I, Figure 2E-G,
Figure 3A, Figure 4B-C, Figure 5A-C), with P <0.05 consid-
ered as statistically significant (P values: * <0.05, ** <0.01,
*** <0.001).
Results
Schwann cells express IL-17 receptors
To evaluate the molecular target of IL-17, IL-17R A and
IL-17R B were analyzed on SCs using immunocytochem-
istry. No inflammatory stimulus was required to induce
IL-17R expression on mouse SCs (mSCs; passage nine).Figure 1 Detection of interleukin 17 (IL-17) receptors (R) IL-17R A and I
and rtPCR analysis. (A-C) immunocytochemistry for IL-17R A, IL-17R B with m
IL-17R mRNA expression of mouse dorsal root ganglia (DRG) co-cultures. Cult
Stimulation gave rise to a strong decrease in IL-17R A expression at the mRNA
expression of 30% (***P ≤0.001). A dose-dependent decrease was detected fo
with 0.5 ng/mL IL-17 (**P ≤0.01) and 14% with 50 ng/mL IL-17 (***P ≤0.001).
mRNA level to 78% for 0.5 ng/mL IL-17 (*P ≤0.05) and 33% for 50 ng/mL IL-1
analysis of variance between the three independent experiments revealed nomSCs revealed that constitutive expression of IL-17R A,
IL-17R B was mainly detectable in a membrane-bound
manner (Figure 1A-F). To evaluate functional expres-
sion, stimulation of mouse DRG cultures with IL-17 for
21 days was performed (Figure 1G-I). We used rSCs for
the rtPCR analysis due to the fact that primary cultures
from rSCs are standardized and provide more reprodu-
cible results (Stettner et al. [29]). Simulation gives rise to
a strong decrease in IL-17R A expression on mRNA
levels after stimulation with 0.5 and 50 ng/mL IL-17
(Figure 1G). Expression levels of both IL-17R B (Figure 1H)
and IL-17 receptor C (IL-17R C) (Figure 1I) decreased in
a dose-dependent manner. These results suggest a func-
tional expression of the receptor.
IL-17 inhibits myelination in vitro
Mouse DRG co-cultures were treated with IL-17 for
21 days followed by Sudan black staining (Figure 2A-D)
to assess the impact on myelination. The ratio of inter-
nodes to neurons decreased to 66%, 55%, and 42% with
0.5, 5 and 50 ng/mL IL-17, respectively (Figure 2E).L-17R B on mouse Schwann cells (SCs), using immunocytochemistry
ainly membrane-bound expression (D-F). (G-I) Real-time PCR results of
ures were treated with IL-17 for 21 days at the indicated concentrations.
level under stimulation with 0.5 and 50 mg/mL IL-17, with a remaining
r IL-17R B and IL-17R C. The remaining expression of IL-17R B was 58%
Similarly, the expression of IL-17R C was significantly reduced at the
7 (***P ≤0.001). For all three receptors and the concentrations applied, an
significant difference. AU, arbitrary unit; DAPI, diamidino-2-phenylindole.
Figure 2 (See legend on next page.)
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Figure 2 Myelin morphology and quantification after interleukin 17 (IL-17) treatment. (A-E) For myelin quantification, mouse dorsal root
ganglia (DRG) co-cultures were exposed to IL-17 for 21 days at the indicated concentrations and subsequently stained, using Sudan black dye.
Images show myelin layer (α) and Schwann cell body (β) are separated from the next internode by Ranvier’s node (γ) and neuronal cell bodies
(δ). In analysis of three independent experiments, quantification revealed a myelin ratio (internodes to neurons) reduction to 66% for 0.5 ng/mL
IL-17 (**P = <0.01), to 55% for 5 ng/mL IL-17 (**P = <0.01), and to 42% for 50 ng/mL IL-17 (**P = <0.01), each compared with control stimulations.
(F) Internodal distances after exposure to IL-17 revealed a significant decrease with 5 ng/mL IL-17 (*P = <0.05) and 50 ng/mL IL-17 (*P = <0.05).
Analysis of variances between the independent experiments revealed no significant difference. (G) Myelin quantification of Sudan-stained DRG
co-cultures after treatment with IL-17, an IL-17-neutralizing antibody (αIL-17ab), and co-stimulation of three independent experiments, respectively. The
myelin-inhibitory effect of IL-17 was reduced by 81% after supplementation with αIL-17ab. Myelination was restored to the base level, similar to
treatment with the antibody alone.
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quantitative myelin synthesis, was reduced significantly
following stimulation with 5 and 50 ng/mL IL-17
(Figure 2F). Measurement of fiber diameter in Sudan
stained cultures did not reveal a significant difference
for the IL-17-treated cultures (data not shown). Co-
stimulation of DRG co-cultures with IL-17 and an IL-
17-neutralizing antibody reduced the myelin inhibitory
effect by about 81% (Figure 2G).
mRNA expression of genes associated with myelination
of rSCs was analyzed after stimulation with IL-17 for
10 days. The mRNA expression of KROX-20 decreased sig-
nificantly with 5 and 50 ng/mL IL-17 (Figure 3A). For P0,
the mRNA expression decreased significantly with 5 ng/mL
IL-17 and decreased non-significantly with 50 ng/mL IL-17
(Figure 3A). Evaluation of myelin morphology using elec-
tron microscopy did not reveal any morphological alter-
ations when compared with control cultures (Figure 3B).
IL-17 does not impede neuronal outgrowth and cell survival
To exclude a direct effect of IL-17 on neuronal outgrowth
and a consecutive effect on myelin synthesis, we performed
neurofilament (NF) staining and quantification in mouse
DRG co-cultures after exposure to IL-17 for 21 days. Neur-
onal fibers did not show a significant reduction in NF after
IL-17 exposure using densitometry analysis, normalized to
background fluorescence (Figure 4A, B).
To further exclude a direct effect of IL-17 on SC sur-
vival, viability assays were performed in rSCs. Stimula-
tion with 0.5 to 50 ng/mL IL-17 did not cause any
significant alterations in SC viability (Figure 4C).
To analyze additional mediators of inflammation and
myelination, the activity of MMPs was assessed. IL-17-
treated DRG co-culture supernatants revealed a signifi-
cant dose-dependent downregulation of MMP-2 activity
and a dose-dependent upregulation of MMP-9 activity,
assessed in gelatine zymography and quantified using
densitometry (Figure 4D, E).
IL-17 increases major histocompatibility complex and
transporter associated with antigen presentation expression
To assess the potential of IL-17 to modify the expression
of molecules associated with antigen transformation andpresentation, MHCI and MHCII, as well as TAPII, were
analyzed using immunocytochemistry and quantified
using densitometry. SCs displayed expression of all three
molecules: MHCI > TAPII >MHCII. MHCI expression
was significantly increased in a dose-dependent manner
after treatment with IL-17 for 72 h (Figure 5A). Com-
pared to MHCI, MHCII exhibited a fainter expression
under control conditions; its expression was slightly but
not significantly increased after 50 ng/mL IL-17, but re-
vealed a significant increase at a concentration of 0.5 ng/
mL IL-17 (Figure 5B). The expression of TAPII was slightly,
though not significantly, increased in a dose-dependent
manner after stimulation with IL-17 (Figure 5C).
Discussion
IL-17 is present in demyelinating peripheral nerve in-
flammation as well as in demyelinating chronic pain
conditions [2,3,8,9]. IL-17 has also been associated with
GBS, a mainly acute demyelination condition of the
PNS [1,12,13,34]. Several studies have revealed that IL-
17 is present primarily during the high-demyelination
stage of these inflammatory and autoimmune diseases
[8-10,12,35], suggesting that a direct SC-driven demye-
linating effect of IL-17 is possible. A prerequisite for a
direct response of SCs to IL-17 is the expression of IL-
17R on SCs, which has been confirmed at both the
RNA and protein level.
Stimulation with IL-17 led to a downregulation on
mRNA level of all IL-17R analyzed. Despite the growing
knowledge about the relevance of IL-17 in various dis-
eases and the fact that the IL-17 receptor is ubiquitously
expressed, little is known about the IL-17R regulation.
Presumably IL-17 signaling is strictly controlled in order
to prevent inflammatory disorders [36,37]. It is known
that IL-21 preferentially induces IL-17R, compared with
IL-2. A blockade of the PI3K pathway led to the upregula-
tion of IL-17R A and constitutive Akt activation is associ-
ated with suppressed IL-17RA expression [38]. Whether
the decrease in expression after IL-17 stimulation detected
in the current study is due to a feedback loop, which is
known for other receptors [39], self-limiting the signal, is
speculative but the data suggests a functional expression
of the receptors on SCs.
Figure 3 mRNA expression of myelin genes P0, and KROX-20 of
rat Schwann cells (rSCs) and myelin morphology after stimulation
with interleukin 17 (IL-17). (A) mRNA expression of myelin genes
P0 and KROX-20 is normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and to control cultures. A significant
decrease in KROX-20 mRNA expression to 51% (**P ≤0.01) was seen
on stimulation with 5 and 50 ng/mL IL-17. P0 mRNA showed a
significant down-regulation to 84% expression with 5 ng/mL IL-17
(*P ≤0.05) and a non-significant down-regulation to 92% expression
with 50 ng/mL IL-17. For P0 and KROX-20 and both concentrations
applied; an analysis of variance between the three independent
experiments revealed no significant difference. (B) Ultrastructure of
the myelin layer of dorsal root ganglia (DRG) co-cultures after IL-17
stimulation (5 ng/mL IL-17, top row) and control cultures (bottom
row). Cultures were stimulated from day 6 after preparation and
fixed after 28 days in vitro. The left images depict a longitudinal
section and the right images a traverse section referring to the
axonal fiber. Myelin showed no morphological alterations after IL-17
stimulation. AU, arbitrary unit; Ax, axon; My, myelin layer.
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http://www.jneuroinflammation.com/content/11/1/63In this study, we analyzed the influence of IL-17 on SC
myelination using the DRG co-culture model. Stimula-
tion with IL-17 resulted in reduced myelin synthesis as
well as a decrease in the length of internodal segments,
an effect that was eliminated by the addition of an IL-
17-neutralizing antibody.
Several inflammatory mediators are able to induce SC
de-differentiation or activation in vivo and in vitro as a
response to pathogens or after mechanical nerve damage[40,41]. In addition to reduced myelination under IL-17
influence, we also detected reduced expression of the
myelinating and pro-myelinating key genes P0 and
KROX-20, for P0 in a concentration of 5 ng/mL and for
KROX-20 in both concentrations applied (5 ng/mL and
50 ng/mL). P0, or myelin protein zero (MPZ), is a struc-
tural component of the myelin layer, necessary for myelin
compaction, whereas KROX-20 is a myelin-associated
transcription factor for pro-myelinating pathways [41-47].
Krox-20 is activated in SCs before the onset of myelin-
ation and its disruption blocks SCs at an early stage in
their differentiation, while radial sorting and attainment of
1:1 relationships between axons and SC are mainly un-
affected [15,45,48,49]. KROX-20 activates a large number
of myelin genes and suppresses molecules of the imma-
ture SC-stage. KROX-20 is a major candidate for holding
the balance between two opposing transcriptional pro-
grams - the immature phenotype versus the myelinating
SC [41]. The discrepancy between the KROX-20 and the
P0 expression is astonishing but may be due to a P0 inde-
pendent signaling pathway or just due to the fact that the
5 ng/mL IL-17 concentration is closer the local IL-17 con-
centration in the inflamed nerve. Robust data on the local
IL-17 concentration within the inflamed peripheral nerve
do not exist so far.
Various compounds are known to mediate direct mye-
lin degrading properties. IL-17 triggers the expression of
inducible nitric oxide (NO) synthase, leading to cytotox-
icity [50,51]. In epithelial, endothelial, and fibroblastic
cells IL-17 induces the secretion of cytokines, such as
IL-6, IL-8, and granulocyte colony-stimulating factor, as
well as prostaglandin E2 (PGE2) [52]. IL-17 also induces
COX-2-dependent PGE2 synthesis and osteoclast differ-
entiation factor gene expression, which leads to bone re-
sorption in rheumatoid arthritis patients [53]. IL-17 also
contributes to the disruption of the blood- brain barrier
by augmented production of reactive oxygen species medi-
ated by nicotinamide adenine dinucleotide phosphate oxi-
dase and xanthine oxidases. The resulting oxidative stress
finally leads to interaction with the cytoskeleton [54].
Thus, a direct toxic effect of IL-17 on the myelin layer
is feasible. To determine if oxidative stress was under-
lying the reduced myelin synthesis following IL-17 treat-
ment, we analyzed the structure of myelin cultures to
detect myelin debris, an observation that would support
the thesis of NO-induced myelin destruction. We de-
tected a reduced amount of myelin, but did not observe
any morphological changes in myelin layers after IL-17
treatment. Although our current findings do not provide
evidence of myelin destruction, we cannot exclude a dir-
ect component of IL-17 induced myelin destruction.
Still, usually infiltrating macrophages cause myelin deb-
ris and scavenge at the site of inflammation [24]; and
this cellular part of the immune system is not present in
Figure 4 Neuronal outgrowth, Schwann cell (SC) viability, and Matrix metalloproteinases (MMP) activity in Interleukin 17 (IL-17)
treated cultures. (A) Neuronal outgrowth was assessed in mouse dorsal root ganglia (DRG) co-cultures after exposure for 21 days to IL-17 at the
indicated concentrations. Representative neurofilament (NF)-stained images of the cultures are depicted. (B) Quantification of NF, using densitometry
analysis, normalized to background fluorescence and control stimulation. Analysis did not reveal a significant alteration in neuronal outgrowth. (C) SC
viability was analyzed after IL-17 stimulation for 7 days at the indicated concentrations. Concentrations between 0.5 and 50 ng/mL did not significantly
alter SC viability. Graph for viability and neurofilament analysis shows results of three independent experiments (D, E). MMP activity in IL-17-treated
DRG co-culture supernatants was analyzed using gelatine zymography and quantified densitometrically. Representative zymography with the
densitometry analysis is depicted. Overall, three independent experiments were performed and analyzed, exhibiting comparable results. AU, arbitrary
unit. IL-17 led to a dose-dependent increase in inflammatory MMP-9 activity (E; 92 kDa), whereas the active and the inactive form of MMP-2 (D; MMP-2
inactive: 72 kDa, active: 62 kDa) decreased in activity.
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study - this gives cause for another explanation of the
scenario.To further exclude an indirect effect of reduced neur-
onal contact, which promotes myelination, we analyzed
neuronal outgrowth but found no significant changes,
Figure 5 Major histocompatibility complex (MHC) I and II as well as Transporter associated with antigen presentation II (TAPII) were
analyzed, using immunocytochemistry on rat Schwann cells (SCs). Corresponding merges are shown in the bottom rows. Treatment of SCs
with IL-17 was performed at concentrations of 0.5 and 50 ng/mL. Graphs to the right show densitometry quantification. SCs showed expression
of MHCI > TAPII > MHCII, which increased after IL-17 treatment. (A) MHCI was mainly detected in the cytoplasm and the expression increased in a
dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P ≤0.01). (B) MHCII revealed a fainter basic expression
emphasizing the nucleus and was found significantly increased after 0.5 ng/mL IL-17 stimulation (**P≤ 0.01). (C) TAPII was detected in the
nucleus and cytoplasm. We detected a dose-dependent tendency but no significantly increased expression after IL-17 stimulation. For MHCI, TAPII
and MHCII and the concentrations applied, analysis of variance between the independent experiments revealed no significant difference. DAPI,
4′, 6-diamidino-2-phenylindole.
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completely rule out that IL-17 simply leads to a delay in
myelin synthesis, but on the basis of the results pre-
sented this seems to be unlikely.
It has been suggested that the increase in IL-17+ cells
following sciatic nerve and spinal cord injury induces SC
apoptosis [55]. In contrast to these results, we found
that SC viability was not affected after IL-17 stimulation,suggesting an apoptosis-independent mechanism for the
decrease in myelination that we observed.
Furthermore, we detected a decreased MMP-2 activity
in DRG culture supernatants, which has been shown
relevant for the induction of myelin synthesis [30], while
pro-inflammatory MMP-9 activity was increased. Our
results are in line with studies reporting an induction of
MMP-9 by IL-17 in various organ systems [56,57].
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transformation and presentation, we further analyzed the
expression of molecules associated with these properties.
MHCI was detected mainly in the cytoplasm, and the ex-
pression was increased by IL-17 in a dose-dependent
manner. Compared with MHCI, MHCII revealed a fainter
basic expression and also an increase in protein expression
after IL-17, with a significantly increased expression at
0.5 ng/mL IL-17, whereas 50 ng/mL just revealed a ten-
dency without statistical significance. Antigenic peptides
are transferred to the endoplasmic reticulum by TAP. We
found that the expression of TAPII increased slightly in a
dose-dependent manner following IL-17 treatment, but
without statistical significance in densitometric analysis.
Thus, we assume that the capacity of SCs to activate
CD8+ and CD4+ T cells, and therefore to act as antigen-
presenting cells in a condition of inflammation, was in-
creased. In accord with our findings, SCs express major
histocompatibility complex molecules and increase the ex-
pression of these molecules under pro-inflammatory con-
ditions in vivo and in vitro [17,18,58-70]. Whether the
change of MHCII and TAP expression in SC after IL-17
stimulation is functional is notional. The results warrant
further functional analysis of MHCII expression in SCs.
Corroborating our results, regulated expression of the
intracellular antigen-processing machinery in peripheral
nerve sections from GBS patients was recently shown
(Meyer zu Horste et al. [17]), and SCs most likely act as
non-professional antigen-presenting cells under certain
conditions. The IL-17-induced increased expression can
be interpreted as an immunological alignment of SCs. This
modulation of SC homeostasis by inflammatory mediators
was reported for interleukins, iNOS, COX-2, and MMPs
as a response to the surrounding environment [20-24].
IL-17 led to no reduction of SC viability, showed no
effect on NF expression, and did not change the struc-
tural myelin formation, but significantly interfered with
SC-mediated myelination. Negative regulators of myelin-
ation which do not necessarily initiate apoptosis such as
c-Jun, Notch, Sox-2, Pax-3, Id2, Krox-24, and Egr-3 are
known. They are found downregulated after initiation of
myelination and may be reactivated after PNS injury
causing SC dedifferentiation [41]. Further inflammatory
mediators, such as TNF-α, can promote phenotype re-
version of mature to immature SCs [25-27,41].
It was suggested before that negative regulators of SC-
myelination may foster neuronal survival and axonal re-
growth but actively suppress myelination. In the context
of neuropathies, such pathways may cause further harm
[41].
Conclusions
In summary, our findings demonstrate the ability of IL-
17 to reduce SC-mediated myelination, an effect thatdoes not appear to involve an indirect effect caused by
either a reduced neuronal stimulus for myelination or a
toxic effect, but rather a direct reprogramming of SC
differentiation. This latter effect may contribute to Wal-
lerian degeneration and equipping of the inflammatory
facilities of SCs in order to modulate the process of
inflammation.
These data provide new insights into the role of IL-17
in the inflammatory response in the PNS that could be
useful in the development of targeted therapies.
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